Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Seelos Therapeutics (DE:NXEN)
FRANKFURT:NXEN
Seelos Therapeutics (NXEN) Stock Price & Analysis
0 Followers
NXEN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.11 - €1.44
Previous Close€0.15
Volume0.00
Average Volume (3M)2.95K
Market Cap
€19.30M
Enterprise Value€28.02M
Total Cash (Recent Filing)$5.80M
Total Debt (Recent Filing)$15.34M
Price to Earnings (P/E)N/A
Beta-0.09
Next Earnings
Apr 26, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding161,379,805
10 Day Avg. Volume913
30 Day Avg. Volume2,947
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-0.45
Price to Sales (P/S)588.23
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.00
Enterprise Value/Gross Profit231.53
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
€2.28Price Target Upside1474.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Seelos Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
16.05% Other Institutional Investors
83.95% Public Companies and
Individual Investors
NXEN FAQ
What was Seelos Therapeutics’s price range in the past 12 months?
Seelos Therapeutics lowest stock price was €0.11 and its highest was €1.44 in the past 12 months.
What is Seelos Therapeutics’s market cap?
Currently, no data Available
When is Seelos Therapeutics’s upcoming earnings report date?
Seelos Therapeutics’s upcoming earnings report date is Apr 26, 2024 which is yesterday.
How were Seelos Therapeutics’s earnings last quarter?
Seelos Therapeutics released its earnings results on Nov 03, 2023. The company reported €0.065 earnings per share for the quarter, beating the consensus estimate of -€0.11 by €0.174.
Is Seelos Therapeutics overvalued?
According to Wall Street analysts Seelos Therapeutics’s price is currently Undervalued.
Does Seelos Therapeutics pay dividends?
Seelos Therapeutics does not currently pay dividends.
What is Seelos Therapeutics’s EPS estimate?
Seelos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Seelos Therapeutics have?
Currently, no data Available
What happened to Seelos Therapeutics’s price movement after its last earnings report?
Seelos Therapeutics reported an EPS of €0.065 in its last earnings report, beating expectations of -€0.11. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of Seelos Therapeutics?
Among the largest hedge funds holding Seelos Therapeutics’s share is Woodline Partners LP. It holds Seelos Therapeutics’s shares valued at 133K.
---
Seelos Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.28 (1474.66% Upside)
€2.28 (1474.66% Upside)
Blogger Sentiment
Bullish
DE:NXEN Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-84.65%
Trailing 12-Months
Company Description
Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio include late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.
---
NXEN Stock 12 Months Forecast
Average Price Target
€2.28
▲(1474.66% Upside)
Technical Analysis
Seelos Therapeutics
―
Apellis Pharmaceuticals
―
Aldeyra Therapeutics
―
Adverum Biotechnologies
―
Onconova Therapeutics
―
Best Analysts Covering NXEN
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-32.77%
reiterated a buy rating 7 months ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -32.77% per trade.
---